![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}
Banseog BioHealth · Current stage
66 pharma, biotech and medtech companies by current stage
For each company we picked its biggest current task from its latest major public events (trials, approvals, new capacity, deals, acquisitions), and we show one year of people flow for the Korean companies at each stage. When choosing where to move, check which stage the company is in first.
6 stages57 Korean companies with a full year on the pension registeras of Sept 2026
One year of people flow, by stage
We split the 57 Korean companies with a full year on Korea’s National Pension Service register by stage; companies outside Korea appear in the lists below only. Each number is the median of values computed company by company, so no single large company decides it. Cells clearly different from the overall row are shaded.
Observed · National Pension Service · Sept 2026
| Stage | Headcount changemedian, 1 year | Companies that grew+3% or more | Companies that shrank−3% or less | People who joinedjoiners ÷ avg. headcount | People who leftleavers ÷ avg. headcount |
|---|---|---|---|---|---|
| All57 companies | +1.7% | 40% | 18% | 20.4% | 19.3% |
| Late clinical · capacity13 companies | +3.6% | 54% | 15% | 25.0% | 21.3% |
| Commercial · sales16 companies | −0.8% | 25% | 25% | 18.3% | 19.8% |
| Global approvals · expansion14 companies | +0.3% | 29% | 14% | 16.5% | 14.5% |
Oct 2025 → Sept 2026, whole-company register · Discovery · preclinical, Early clinical · first deals, M&A · integration: fewer than 10 companies, hidden · no company names · observed, not a forecast · updated monthly · source: National Pension Service (data.go.kr)
Discovery · preclinical4 companies
Finding candidates and running preclinical studies
Fewer than 10 Korean companies with a full year on the register at this stage, so no people flow is shown.
- DT&CROCRO
Announced development of an integrated platform using AI to screen toxicity study tissue images and link them to study data
- AlteogenBiotech
Signed an option and license agreement with Novartis to develop subcutaneous formulations of multiple products using ALT-B4
- LigaChem BiosciencesBiotech
Announced US Fast Track designation for platform-based candidate SOT106 and plans to initiate a first-in-human trial
- Hanmi Fine ChemicalCDMO & bioprocess
Joined an AI project for active pharmaceutical ingredient process optimization, taking responsibility for GMP-site and batch-data validation
Early clinical · first deals6 companies
Entering first clinical trials or signing first licensing and supply deals
Fewer than 10 Korean companies with a full year on the register at this stage, so no people flow is shown.
- GC CellBiotech
Confirmed completion of Phase 1a recruitment for a CAR-NK candidate and signed an agreement on subsequent clinical trial design
- GC BiopharmaPharma
Preparing for first dosing after announcing South Korean Phase 2 clinical trial authorization for the COVID-19 mRNA vaccine GC4006A · Also seen: Discovery · preclinical
- RP BioBiotech
Added a new contract manufacturing product by starting initial production of a turmeric extract product for cognitive function and announcing plans to supply partners
- SK bioscienceBiotech
Submitted a pediatric Phase 1b application for RSV preventive antibody RSM01, preparing for infant development after initial validation in adults
- ABL BioBiotech
Announced US Phase 1 entry for two bispecific ADC candidates while pursuing blood-brain barrier delivery platform research · Also seen: Discovery · preclinical
- ImmuneOncia TherapeuticsBiotech
Obtained interim Phase 1b results for a CD47 antibody in triple-negative breast cancer and announced acceptance for conference presentation
Late clinical · capacity18 companies
Running late-stage trials or adding manufacturing capacity
One-year people flow13 Korean companies at this stage · median headcount change +3.6% (all +1.7%) · grew 54%, shrank 15% · joined 25.0%, left 21.3% (all 20.4%, 19.3%)
Signed a major foot-and-mouth disease vaccine supply agreement with the Public Procurement Service and disclosed a contract period amendment following issuance of a test report
Advancing late-stage hemophilia drug development after reporting completion of the Japanese regulatory filing for a Hemlibra autoinjector formulation
- BinexCDMO & bioprocess
Expanding its production base during the Osong plant expansion, with a European GMP inspection pass and first commercial production order announced · Also seen: Early clinical · first deals
- EuBiologicsBiotech
Secured contracted supply volumes from its own production facilities through a KRW 10.5 billion cholera vaccine supply agreement with UNICEF Mozambique
- OPTUS PharmaceuticalPharma
Expanded single-use eye drop production capacity with completion and occupancy approval of Osong Plant 2, preparing subsequent product approval and operating procedures
- LOTTE BIOLOGICSCDMO & bioprocess
Completed construction and obtained occupancy approval for Songdo Plant 1, and signed a long-term manufacturing agreement with Alvotech using its Syracuse facility in the US · Also seen: Global approvals · expansion
- Daewoong PharmaceuticalPharma
Established a new advanced biopharmaceutical facility in Songdo to expand clinical research production capacity and announced manufacturing authorization and operating plans
- Astellas PharmaJapan
Advancing late-stage development with first-patient dosing announced in a Phase 3 trial of setidegrasib for KRAS G12D-mutated lung cancer
- Jeil PharmaceuticalPharma
Completed a KRW 24.9 billion expansion of the Baegam plant's solid dosage building and preparing new equipment qualification and product-specific approval amendments
- Eli LillyUnited States
Expanding US small-molecule manufacturing facilities with a groundbreaking ceremony for a USD 6.5 billion active pharmaceutical ingredient plant in Houston
- BoryungPharma
Expanded overseas pharmaceutical supply with a seven-year agreement with China's Yifan Pharmaceutical following the acquisition of the global Taxotere business · Also seen: Global approvals · expansion
- ST PharmCDMO & bioprocess
Expanded CDMO orders with a KRW 91.3 billion oligonucleotide drug substance supply agreement with a US biotech company
- Hanmi PharmaceuticalPharma
Completed the South Korean marketing authorization application for efpeglenatide and launched an AI quality operations project at the Pyeongtaek Bio Plant · Also seen: Commercial · sales
- AmgenUnited States
Advancing MariTide Phase 3 trials for weight management and expanding Phase 3 recruitment for cardiovascular disease, heart failure and sleep apnea · Also seen: Commercial · sales
- Regeneron PharmaceuticalsUnited States
Advancing late-stage development with acceptance of US and European cemdisiran regulatory applications while expanding existing antibody drug sales · Also seen: Commercial · sales
- Boryung BiopharmaPharma
Secured substantial South Korean supply volumes with confirmation of a procurement agreement for 1.93 million doses of Moderna's COVID-19 vaccine
- Shin Poong PharmPharma
Announced plans to advance a stroke candidate into Phase 3 and invest in production facilities, while expanding the use of an existing treatment · Also seen: Commercial · sales
- KyongBo PharmaceuticalPharma
Building an integrated contract development and manufacturing base through investment in ADC linker-payload manufacturing facilities and research laboratories · Also seen: Discovery · preclinical
Commercial · sales18 companies
Selling approved products and running sales and manufacturing
One-year people flow16 Korean companies at this stage · median headcount change −0.8% (all +1.7%) · grew 25%, shrank 25% · joined 18.3%, left 19.8% (all 20.4%, 19.3%)
- Dongwha PharmaceuticalPharma
Continuing to expand its OTC and prescription drug portfolio with a new official news announcement of the Panlong oral solution launch for motion sickness
- Celltrion PharmPharma
Expanded its existing biosimilar lineup by starting South Korean sales of Yuflyma 40 mg safety-device prefilled syringes
- Dong-A STPharma
Expanded its medical device business using its existing healthcare institution sales network through an exclusive South Korean sales agreement for an AI gait analysis solution
- Daewon PharmaceuticalPharma
Expanded its prescription and OTC drug portfolio by launching Pancrawon Tab. 25000 for exocrine pancreatic dysfunction
- HuonsPharma
Expanded its vaccine business through an exclusive South Korean distribution agreement for IMOJEV and disclosed preclinical results for a Crohn's disease candidate · Also seen: Discovery · preclinical
- Hanlim PharmPharma
Expanded the prescribing and distribution base for an existing prescription drug after reported major-hospital formulary approval of two strengths of a rheumatoid arthritis treatment
- Chong Kun DangPharma
Held a launch symposium for gastritis treatment G-TEC, adding an internally developed botanical drug to its South Korean commercial portfolio
- BC World PharmPharma
Expanded its existing prescription drug portfolio by officially posting the launch of dyslipidemia combination drug Staphinoh tablets in a company press release
- Daiichi SankyoJapan
Expanded approved product indications with additional Japanese first-line metastatic breast cancer approvals for ENHERTU and DATROWAY
- CTCBIOPharma
Announced first-half profitability across all three divisions and improved operating results through veterinary drug, human drug and ingredients sales and cost efficiency measures
- Whanin PharmaceuticalPharma
Expanded its capsule-centered neuropsychiatric drug lineup with the announced South Korean launch of atomoxetine tablets in six strengths
- Kuhnil PharmaceuticalPharma
Expanded the scope of an existing commercial pediatric insomnia treatment with an indication extension to sleep disorders associated with ADHD
- HK inno.NPharma
Expanding therapeutic coverage and the sales base for products launched in South Korea and overseas after announcing K-CAB's sixth South Korean indication approval · Also seen: Global approvals · expansion
- CKD BiOPharma
Continued medical education and marketing for an existing commercial product with a symposium marking the first anniversary of the Tyemvers botulinum toxin injection launch
- Ilsung ISPharma
Strengthened operations and research through completed workplace AI pilot validation in five departments and a pharmaceutical co-development agreement · Also seen: Discovery · preclinical
- Kwangdong PharmaceuticalPharma
Established a South Korean commercialization base for a rare disease drug by announcing marketing authorization for Fabry disease treatment Elfabrio
- SK BiopharmaceuticalsPharma
Reported growth in US cenobamate sales and prescriptions and completed a US new drug application for its suspension formulation · Also seen: Late clinical · capacity
Expanded its pharmaceutical sales portfolio with the South Korean launch of Telamchlow, a low-dose triple-combination hypertension drug co-developed with Yuhan
Global approvals · expansion15 companies
Winning approvals abroad or moving into overseas sales and local sites
One-year people flow14 Korean companies at this stage · median headcount change +0.3% (all +1.7%) · grew 29%, shrank 14% · joined 16.5%, left 14.5% (all 20.4%, 19.3%)
- Samsung BioepisBiotech
Signed a ten-year supply agreement for an eculizumab biosimilar with Brazilian partners and announced production technology transfer plans · Also seen: Late clinical · capacity
- Dongkook PharmaceuticalPharma
Expanded Centellian24 distribution through major US retailers and resolved to pursue a company name change for global business expansion
- MedytoxBiotech
Expanded its locally approved filler lineup and overseas commercialization base with Chinese marketing authorization for Neuramis Volume Lidocaine
- CHA BiotechBiotech
Expanded overseas CDMO services as its US subsidiary took on protein material process development for a local company · Also seen: Discovery · preclinical
- Korea United PharmPharma
Expanded the local sales scope of its export business through a three-year oncology drug supply agreement for Malaysian government hospitals
- CelltrionBiotech
Expanded its European biosimilar lineup and sales footprint by launching Omlyclo 300 mg in Germany, the UK and France · Also seen: Commercial · sales
- HugelBiotech
Expanded overseas distribution by launching the botulinum toxin LETYBO in India and bringing WELLAGE to US Sephora stores · Also seen: Commercial · sales
Announced US FDA approval of ORZEYFUL for narcolepsy type 1 and preparing follow-up steps for its US launch
- SD BiosensorMedtech & diagnostics
Secured eligibility for overseas public procurement after confirmation of a tuberculosis molecular diagnostic product's inclusion on the Global Fund procurement list
- SeegeneMedtech & diagnostics
Expanded its US diagnostic product supply base and lineup after its US subsidiary's multiplex PCR assay received FDA Emergency Use Authorization
- BionoteBiotech
US subsidiary launched the modular veterinary diagnostic analyzer Vcheck C10 and began local distribution and sales
- Samil PharmaceuticalPharma
Expanded overseas ophthalmology distribution and sales rights through an exclusive Vietnamese commercialization agreement with Formosa for eye drop APP13007
- YuhanPharma
Confirmed overseas business expansion by announcing European commercialization of the lazertinib combination regimen and plans to receive an associated milestone payment · Also seen: Commercial · sales
- SK PlasmaPharma
Pursuing local production and quality management systems through a EUR 65 million plasma fractionation product technology transfer agreement with its Turkish joint venture
- Genuone SciencesCDMO & bioprocess
Expanded overseas sales with initial generic product launches in Mexico and Thailand and an announced entry into China's OTC drug market
M&A · integration5 companies
Combining companies after an acquisition or merger
Fewer than 10 Korean companies with a full year on the register at this stage, so no people flow is shown.
- Samsung BiologicsCDMO & bioprocess
Reported satisfaction of the acceptance condition for the PolyPeptide tender offer while pursuing acquisition financing and production expansion at Plant 5 · Also seen: Late clinical · capacity
- BioInfraBiotech
Pursuing organizational integration of genotoxic impurity analytical testing after board approval of the absorption of wholly owned subsidiary U&Infra
- JW PharmaceuticalPharma
Acquired full ownership of a biotech investment firm for KRW 30.7 billion, adding a subsidiary connecting drug discovery, co-development and in-licensing
- Vertex PharmaceuticalsUnited States
Completed the Crinetics acquisition, expanded the integration function and added rare endocrine disease treatments to its business · Also seen: Commercial · sales
- Ildong PharmaceuticalPharma
Absorbed drug development subsidiary UNOVIA, assuming its rights and obligations and reintegrating R&D into the parent company
Chosen from the latest major public event. Each company page shows the dated evidence and sources. The people flow is the median of each Korean company’s one-year change on the pension register within a stage; it is not any one company’s hiring. No forecasts.